A Diagnostic for the Early Detection of Bladder Cancer

Last updated: August 19, 2024
Sponsor: Cedars-Sinai Medical Center
Overall Status: Active - Recruiting

Phase

N/A

Condition

Urothelial Cancer

Urothelial Carcinoma

Bladder Cancer

Treatment

N/A

Clinical Study ID

NCT05347342
IIT2021-19-Furyua-EarlyDx
R01CA277810
  • Ages > 18
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

To improve upon the non-invasive detection of bladder cancer by further validating a multiplex ELISA assay directed at a bladder cancer-associated diagnostic signature in voided urine samples of patients with a high risk of developing bladder cancer.

Eligibility Criteria

Inclusion

Inclusion Criteria:

Participants must be:

  1. Age 50 years or older

  2. >20 pack year history of tobacco exposure

  3. Free of any malignancy except for the following: adequately treated basal cell orsquamous cell skin cancer, in situ cervical cancer, adequately treated Stage I or IIcancer from which the patient is currently in complete remission, or any othercancer from which the patient has been disease free for five years. Patients withlocalized prostate cancer who are being followed by an active surveillance programare also eligible.

  4. Scheduled to be evaluated in the Pulmonary Rehab Clinic or Lung Cancer ScreeningClinic

  5. Willing and able to give written informed consent

  6. Willing to provide voided urine sample

  7. Be able and willing to complete semi-annual research clinic visits for 4 years

Exclusion

Exclusion Criteria:

Participants must not have:

  1. History of hematuria (microscopic or gross) within 2 years of signing consent.

  2. Previous history of bladder cancer

  3. A known active urinary tract infection or urinary retention

  4. An active stone disease (renal or bladder) or renal insufficiency (creatinine >2.0mg/dL) - Serum creatinine value can be up to 2 years before consent, otherwiserepeat.

  5. An ureteral stents, nephrostomy tubes or bowel interposition

  6. A recent genitourinary instrumentation (within 7 days prior to collection of voidedurine sample)

Study Design

Total Participants: 200
Study Start date:
April 29, 2022
Estimated Completion Date:
December 30, 2026

Study Description

Environmental exposures, specifically tobacco smoke, increases the risk of many cancers, including bladder cancer. To date, there are no diagnostics capable of detecting bladder cancer early, that is prior to clinical presentation. Because of this severe limitation, nearly 30% of patients initially present with stage 2 and higher bladder cancer. Stage 2 bladder cancer has a 5-year survival of 50%, while stage 3/4 have a 5-year survival of <20%. Ideally, bladder cancer would be preventable. Unfortunate, this has not come to fruition. If these stage 2-4 bladder cancer cases could be detected at Stage 1 (5-yr survival >94%), then its possible to see an improvement in bladder cancer survival rates (21-23).

in this study, a urine-based diagnostic that possesses the potential to accurately identify patients who harbor bladder cancer prior to clinical manifestation will be tested.

Connect with a study center

  • Long Beach VA Healthcare System

    Long Beach, California 90712
    United States

    Active - Recruiting

  • Cedars-Sinai Medical Center

    Los Angeles, California 90048
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.